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A B S T R A C T
The aim of the study was to clarify whether serum levels of proinflammatory cytokine interleukin-6 (IL-6) could be a
useful marker in prostate diseases. Serum IL-6 was determined prior to prostate biopsy procedure in 82 patients with
prostate adenocarcinoma (PCa), 25 patients with benign prostatic hyperplasia (BPH), 24 patients with high-grade pros-
tatic intraepithelial neoplasia (PIN) and 17 patients with chronic prostatitis. Serum IL-6 levels were compared with to-
tal PSA (tPSA), free PSA (fPSA) and the free/total ratio (f/tPSA) serum levels. Statistically significant difference was not
found in serum IL-6 levels among the four groups (p=0.088). However, the patients with poorly differentiated PCa with
Gleason score (GS) 4+3=7 and >7 had significantly higher serum IL-6 levels than the patients with moderately differ-
entiated PCa with GS 3+4=7 and <7 (p=0.007). The findings suggest that serum IL-6 level might be a potentially use-
ful marker for poorly differentiated PCa.
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Introduction
Prostate cancer is the most common non-skin cancer
among adult men worldwide1. Screening has been advo-
cated as a means of detecting PCa in the early stages to
decrease overall and disease specific mortality2. An ele-
vated tPSA level can reflect the presence of cancer but can
also be caused by BPH, high-grade PIN, infection, and/or
chronic inflammation. All prostate epithelial cells, whe-
ther normal, hyperplastic or cancerous, synthesize pros-
tate specific antigen. Neoplastic cells produce somewhat
lower tissue levels of tPSA compared to BPH cells al-
though both conditions cause tPSA elevation in the blood.
Therefore, it has been suggested that tPSA should be con-
sidered as a marker of BPH-related prostate volume,
growth, and outcome rather than a reliable marker of
PCa3. PSA is not the ideal biomarker for PCa detection
and management. Elevated levels of IL-6 in men with lo-
cal PCa and advanced disease made IL-6 candidate bio-
marker for PCa development and progression4. IL-6 is a
pleiotropic cytokine involved in prostate regulation and in
PCa development and progression. IL-6 acts as a paracri-
ne and autocrine growth stimulator in benign and tumor
prostate cancer cells. Recent evidence suggests that the
presence of inflammatory factors and cytokines at the tu-
mor site results in tumor cell survival, proliferation, inva-
sion and metastasis5. Clinical observations have demon-
strated increased IL-6 levels in plasma and serum from
patients with castration-resistant prostate cancer (CRPC)6,7,
metastatic PCa8, biochemical recurrence9 and poorer over-
all survival10. In the present study, the aim was to com-
pare clinical significance of serum IL-6 levels with classic
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tumor markers (tPSA, fPSA and f/tPSA) in the diagnosis
of patients prior to prostate biopsy. In addition, it was at-
tempted to clarify whether serum IL-6 levels could be a
useful marker in the diagnosis of various prostate diseases.
Materials and Methods
The research has been carried out in accordance with
the Declaration of Helsinki and approved by the Ethics
Committee of our hospital. The written consent was ob-
tained from all patients after full explanation of the pro-
cedure. No patients had evidence of active infection or in-
flammatory disease, other malignant visceral tumor and
none were under any treatment for PCa at the time of ex-
amination. Patients who underwent digital rectal exami-
nation (DRE) or other prostatic manipulation a week
prior to prostate biopsy were excluded from the study.
Trans-rectal ultrasound (TRUS) guided prostate biopsy
was performed on total of 148 patients (aged 33–82) who
had tPSA level >4 ng/mL in the serum, and/or positive
DRE and/or positive TRUS. Prostate disease was con-
firmed by needle biopsy of the prostate (twelve-core pros-
tate biopsy samples). A total of 82 patients had PCa, 25
patients had BPH, 24 patients had high-grade PIN and
17 had chronic prostatitis. Out of 82 patients with biopsy
confirmed PCa, 61 patients had pathohistologically con-
firmed moderately differentiated PCa (GS 3+4=7 and
<7) and 21 patients had poorly differentiated PCa (GS
4+3=7 and >7). Blood for the measurement of serum
IL-6 was collected into nonheparinized tubus prior to
prostate biopsy and serum was separated within 1 hour
of blood collection. The serum was stored at –70 °C and
then thawed just prior to testing. Serum IL-6 levels were
analyzed according to the manufacturer’s instructions
with a highly sensitive enzyme linked immunoadsorbent
assay (ELISA) using a sandwich technique (Quantikine
human IL-6 immunoassay, R&D Systems). The lowest
detectable serum IL-6 level was 1.5 pg/mL. Data were
shown as median and total range. Prostate specific mark-
ers tPSA, fPSA and f/tPSA were determined in blood
samples immediately upon blood collection.
Statistics
Statistical Package for the Social Sciences (SPSS) ver-
sion 17 was used for the statistical analysis. All of the
data were expressed as median and total range. Since the
Kolmogorov-Smirnov test (the K-S test) showed that the
distribution of dependent variables differed from nor-
mality, the nonparametric tests for independent samples
(the Kruskal-Wallis test and the Mann-Whitney U-test)
were used for data analysis. The significance level of p<
0.05 was considered to be statistically significant. The re-
lationship between the variables IL-6 and tPSA was cal-
culated with the Spearman correlation coefficient test. The
lowest possible detectible serum IL-6 level was 1.5 pg/mL.
Results
Table 1 shows the data for the four groups of patients
with PCa, BPH, high-grade PIN and chronic prostatitis.
Median and range of patients’ age, serum IL-6 levels, se-
rum tPSA levels, serum fPSA and serum f/tPSA levels
are shown for each group.
Table 1 shows that the study included 148 patients,
out of which 82 patients had PCa, 25 patients had BPH,
24 patients had high-grade PIN and 17 patients had
prostatitis. Median for all patients was C=67 years (ran-
ge 33–82). The Kruskal-Wallis test did not show a statis-
tically significant difference in the age of the patients
with different diagnoses (p=0.121). Also, there was no
statistically significant difference in serum IL-6 levels in
patients with PCa, BPH, high-grade PIN and prostatitis
(p=0.088). Moreover, the tPSA variable showed a statis-
tically significant difference among all four groups of pa-
tients (p=0.000). The Mann-Whitney U-test was used as
a post-hoc test. It determined a statistically significant
difference between PCa and high-grade PIN (p=0.001),
as well as a statistically significant difference between
PCa and BPH (p=0.001). In short, the patients with PCa
had higher tPSA levels than the patients with high-grade
PIN and BPH. Furthermore, there was no statistically
significant difference in tPSA levels between PCa and
prostatitis patients (p=0.052). Also, the Kruskal-Wallis
test determined that there was a statistically significant
difference among the patients with all four diagnosis in
the f/tPSA levels (p=0.000). The post-hoc analysis deter-
mined a statistically significant difference between the
patients with PCa and high-grade PIN (p=0.000), as well
as the difference between the patients with PCa and
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TABLE 1
PREBIOPTIC SERUM LEVELS OF IL-6, tPSA, fPSA AND f/tPSA
age (year) IL-6 (pg/mL) tPSA (ng/mL) fPSA (ng/mL) f/tPSA (%)
N Median Range Median Range Median Range Median Range Median Range
PCa 82 67 33–82 2.09 1.49–16.75 9.20* 2.1–686.3 1.35 0.13–60.90 16* 5–33
PIN 24 67.50 54–80 2.16 1.49–5.93 4.80 1.4–20.0 1.20 0.47–4.17 22 17–37
BPH 25 62 43–76 1.63 1.49–3.84 5.70 1.7–15.3 1.22 0.28–2.72 20 9–40
Prostatitis 17 69 53–73 1.55 1.49–4.61 6.10 1.9–17.8 1.19 0.52–8.12 20 14–46
PCa – prostate adenocarcinoma, PIN – high–grade prostatic intraepithelial neoplasia, BPH – benign prostate hyperplasia, IL-6 –
interleukin-6, tPSA – total prostate specific antigen, fPSA – free prostate specific antigen, f/tPSA – free/total prostate specific antigen
ratio; *p<0.05 considered statistically significant
BPH (p=0.003) and the patients with PCa and prostati-
tis (p=0.004). To sum up, the patients with PCa had the
lowest t/fPSA levels among the four groups of patients.
Finally, a statistically significant difference was not found
in fPSA levels among the four groups of patients (p=
0.631). Table 2 shows the difference between the groups
of patients with moderately (GS 3+4=7 and <7) and
poorly differentiated (GS 4+3=7 and >7) PCa.
The group of patients with poorly differentiated (GS
4+3=7 and >7) PCa had higher serum IL-6 levels than
the patients with moderately differentiated (GS 3+4=7
and <7) PCa (p=0.007). Furthermore, the nonparame-
tric Mann-Whitney U-test for independent samples de-
termined a statistically significant difference in the tPSA
levels between the two groups of PCa patients in which
the patients with poorly differentiated PCa (GS 4+3=7
and >7) had higher tPSA than those with moderately
differentiated (GS 3+4=7 and <7) PCa (p=0.000). Also,
a statistically significant difference was found when com-
pared fPSA within the two groups of PCa patients show-
ing that the patients with poorly differentiated (GS 4+
3=7 and >7) PCa had higher fPSA levels (p=0.000).
However, there was no statistically significant difference
in patients with moderately (GS 3+4=7 and <7) and
poorly differentiated (GS 4+3=7 and >7) PCa in the
f/tPSA levels (p=0.086). Furthermore, patients with mo-
derately (GS 3+4=7 and <7) and poorly differentiated
(GS 4+3=7 and >7) PCa did not show statistically sig-
nificant difference in their age (p=0.098). The Spearman
correlation coefficient test showed the positive correla-
tion between serum IL-6 and PSA levels in patients with
PCa (p=0.001).
Discussion
Currently, PSA is the putative biomarker for PCa
screening. Although PSA testing has high sensibility, its
specificity is rather low, causing clinicians to have doubts
with regard to biopsying, since increased false-positive
rates, overdiagnosis and overtreatment have been re-
ported to be associated with PSA testing11. Therefore,
novel biomarkers are needed to improve identification of
men at risk of having PCa and predict the natural behav-
ior of the prostate tumor. The use of more sensitive and
specific biomarkers will be an appropriate strategy for
disease diagnosis, disease staging, disease prognosis, pre-
dicting and monitoring clinical response to the therapy.
Clinical and biological data confirm the role of the
proinflammatory cytokine IL-6 in PCa and support the in-
clusion of IL-6 as a marker in patients with PCa. De
Marzo et al.13 described the development of chronic in-
flammation related to infectious and non-infectious agents,
called proliferative inflammatory atrophy (PIA), as pre-
cursor lesions of PCa. Nakashima et al.14 reported that
IL-6 is independently associated with survival in a series
of 74 patients with PCa. IL-6 predicts biochemical recur-
rence in patients treated with radical prostatectomy (RP)15.
The Gleason grading system remains one of the most
powerful prognostic factors for PCa, and plays a crucial
role in the prediction of metastatic progression after
RP16,17. Serum IL-6 was significantly elevated in patients
with Gleason score >6 (GS>6)18. Similarly, the data of
serum IL-6 levels obtained in the present study showed
elevated levels in poorly differentiated PCa patients (GS
4+3=7 and >7). Additionally, Ogui} et al. concluded that
higher tumor grade and positive surgical margins are in-
dicators of a worse prognosis in patients19.
The National Comprehensive Cancer Network (NCCN)
guidelines suggested that PCa diagnosed with a patho-
logical GS>7 requires aggressive local radiation and no
RP20. Clinicians are in need of simple diagnostic modali-
ties, available at initial diagnosis, which may be em-
ployed to estimate the clinical significance of cancer and
guide their treatment decisions. TRUS guided true cut
biopsy is a gold standard in PCa diagnostics21. The diag-
nosis of PCa is based on a combination of DRE, testing of
PSA and the TRUS-biopsy. Testing of PSA and DRE are
both limited with regard to their low sensitivity and spec-
ificity. A serum PSA measurement of 4 ng/ml is often still
regarded as the threshold above which prostate biopsy is
performed22. Several studies have shown an increase in
sensitivities and specificities, primarily in the tPSA ran-
ge of lower 10 ng/mL, for the f/tPSA ratio. They confirm
that f/tPSA can better distinguish between patients with
PCa from patients with BPH23,24. Similarly, the present
study confirmed the same evidence for the f/tPSA ratio,
which was the lowest for patients with PCa among the
four groups of patients. Moreover, our study found that
tPSA is higher in poorly differentiated PCa than in mod-
erately differentiated PCa.
To improve the early detection of PCa, various PSA
forms seem to be an established way for the early detec-
tion of PCa. Early detection measures, such as PSA test-
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TABLE 2
PREBIOPTIC SERUM LEVELS OF IL-6, tPSA, fPSA AND f/tPSA IN THE GROUP OF PATIENTS WITH PCa WITH MODERATELY
AND POORLY DIFFERENTIATED PCa
age (year) IL-6 (pg/mL) tPSA (ng/mL) fPSA(ng/mL) f/tPSA (%)
GS N Median Range Median Range Median Range Median Range Median Range
£7 3+4=7 61 66 33–81 1.76 1.49–16.75 6.90 2.1–42.6 1.18 0.31–6.73 16 7–33
³7 4+3=7 21 70 49–82 3.30* 1.49–10.67 54.30* 3.3–686.3 7.74* 0.13–60.90 10 5–30
GS – Gleason score, IL-6 – interleukin-6, tPSA – total prostate specific antigen, fPSA – free prostate specific antigen, f/tPSA – free/to-
tal prostate specific antigen ratio; *p<0.05 considered statistically significant
ing and TRUS guided prostate biopsy combined with the
raised public awareness of the disease, most probably re-
sulted in an increase of incidence25. It is of great interest
to the urologists to avoid unnecessary biopsies and antic-
ipate the distress of treated patients26,27. Because of the
aforementioned limitations of the different biomarkers,
further studies are necessary to find improved markers
for the detection of PCa to reduce the number of patients
who undergo a prostate biopsy without having PCa.
In conclusion, there was no significant difference in
serum IL-6 collected prior to prostate biopsy procedure
in patients with PCa, BPH, high-grade PIN and prostati-
tis. Total PSA is a marker with a low specificity in PCa
detection but f/tPSA can better distinguish between pa-
tients with PCa from the patients with BPH, high-grade
PIN and prostatitis. IL-6 can be an additional marker in
detection of poorly differentiated PCa patients (GS 4+
3=7 and >7), and thus can provide some helpful guide-
lines for its adequate management and treatment. Lar-
ger prospective studies and the standardization of the as-
says for the measurement of IL-6 are required to confirm
the role of these cytokines as tumor markers in PCa.
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USPOREDBA KLINI^KE ZNA^AJNOSTI PROINFLAMATORNOG PROTEINA INTERLEUKINA-6
U SERUMU I KLASI^NIH TUMORSKIH MARKERA UKUPNOG PSA, SLOBODNOG PSA I
SLOBODNI/UKUPNI PSA PRIJE BIOPSIJE PROSTATE
S A @ E T A K
Cilj ove studije je bio razjasniti mo`e li razina proinflamatornog citokina, interleukina-6 (IL-6) u serumu biti korisni
marker kod bolesti prostate. Serumski IL-6 je bio odre|en prije biopsije prostate u 82 pacijenta s adenokarcinomom
prostate (PCa), 25 pacijenata s benignom hiperplazijom prostate (BPH), 24 pacijenta s intraepitelnom neoplazijom
visokog stupnja (PIN) i 17 pacijenata s kroni~nim prostatitisom. Razina serumskog IL-6 je uspore|ena s ukupnim PSA
(tPSA), slobodnim PSA (fPSA) i omjerom slobodni/totalni PSA (f/tPSA) u serumu. Statisti~ki zna~ajna razlika nije
na|ena u razini serumskog IL-6 izme|u ~etiri grupe (p=0.088). Me|utim, pacijenti s lo{e diferenciranim PCa s Gleason
»scoreom« (GS) 4+3=7 i >7 imali su zna~ajno vi{e razine serumskog IL-6 nego pacijenti sa srednje diferenciranim PCa
s GS 3+4=7 i <7 (p=0.007). Rezultati sugeriraju da bi razina serumskog IL-6 mogla biti potencijalni korisni marker
kod slabo diferenciranog PCa.
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